What is Peca Labs?
Peca Labs operates at the intersection of material science and clinical cardiology, specializing in the development of innovative implantable devices. Their core product portfolio, which includes the exGraft, exGraft II, MASA Valve, and STEALTH systems, utilizes advanced polymeric materials to enhance the longevity and performance of vascular interventions. By focusing on high-precision customization and improved visualization, Peca Labs addresses critical gaps in current cardiovascular treatment protocols. The company serves a specialized market of healthcare providers and surgical institutions, positioning itself as a high-growth player in the medical technology landscape. Their commitment to engineering excellence and patient-centric design serves as a primary differentiator in a competitive field dominated by legacy medical device manufacturers.
How much funding has Peca Labs raised?
Peca Labs has raised a total of $5.1M across 4 funding rounds:
Series A
$2.8M
Private Equity
$749K
Private Equity
$1.4M
Debt
$150K
Series A (2015): $2.8M with participation from Blue Tree Capital Group, LLC.
Private Equity (2016): $749K, investors not publicly disclosed
Private Equity (2018): $1.4M, investors not publicly disclosed
Debt (2021): $150K featuring PPP
Key Investors in Peca Labs
Blue Tree Capital Group, LLC.
An investment entity that has historically participated in early-stage financing, providing essential capital to support the initial commercialization efforts of emerging medical technology firms.
Undisclosed Investor
An institutional backer participating in the firm's private equity rounds to support long-term growth and infrastructure development.
PPP
Public-Private Partnership
What's next for Peca Labs?
With the recent infusion of capital, Peca Labs is well-positioned to accelerate its clinical validation programs and expand its commercial footprint. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the anticipated demand for their next-generation vascular grafts. Furthermore, the company is expected to leverage its current financial standing to deepen its research and development pipeline, potentially exploring new indications for its polymeric platform. As the firm matures, the emphasis will remain on securing regulatory milestones and establishing long-term partnerships with major hospital networks, ensuring that their technological advancements translate into improved clinical outcomes and sustained market share growth within the global cardiovascular device industry.
See full Peca Labs company page
